Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 7/20 | 0.48 |
| ▸ | PTGER3 | P43115 | 9/20 | 0.45 |
| ▸ | CTSA | P10619 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL687524 | 0.92 | PTGER3 (0.45) | LCKPTGER3CTSAALDH1A1THRB | |
| SCHEMBL686620 | 0.91 | PTGER3 (0.50) | LCKPTGER3CTSAALDH1A1MAPT | |
| SCHEMBL687770 | 0.89 | PTGER3 (0.47) | LCKPTGER3CTSAMAPT | |
| SCHEMBL686842 | 0.88 | PTGER3 (0.45) | LCKPTGER3CTSAALDH1A1THRB | |
| SCHEMBL27741954 | 0.88 | PTGER3 (0.44) | LCKPTGER3ALDH1A1 | |
| SCHEMBL688519 | 0.88 | PTGER3 (0.46) | LCKPTGER3ALDH1A1 | |
| SCHEMBL688765 | 0.86 | PTGER3 (0.49) | PTGER3CTSAMAPT | |
| SCHEMBL687791 | 0.86 | PTGER3 (0.43) | PTGER3CTSAALDH1A1THRBHPGD | |
| SCHEMBL687769 | 0.86 | PTGER3 (0.62) | PTGER3ALDH1A1NPSR1MAPT | |
| SCHEMBL686762 | 0.85 | PTGER3 (0.51) | PTGER3CTSAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1176956-B1 | CARBOXYLIC ACID DERIVATIVES THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS | ENCYSIVE PHARMACEUTICALS INC (US) | 2008-01-09 | — | — | EP | claimed |
| US-6972296-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC. (US) | 2005-12-06 | — | — | US | claimed |
| US-20040063955-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC. | 2004-04-01 | — | — | US | claimed |
| JP-2002544161-A | — | — | 2002-12-24 | — | — | JP | claimed |
| WO-2000067746-A9 | CARBOXYLIC ACID DERIVATIVES THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS | TEXAS BIOTECHNOLOGY CORP (US) | 2002-08-29 | — | — | WO | claimed |
| EP-1176956-A4 | CARBOXYLIC ACID DERIVATIVES THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS | TEXAS BIOTECHNOLOGY CORP (US) | 2002-08-28 | — | — | EP | claimed |
| EP-1203766-A2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2002-05-08 | — | — | EP | claimed |
| EP-1176956-A1 | CARBOXYLIC ACID DERIVATIVES THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2002-02-06 | — | — | EP | claimed |
| WO-2000067746-A1 | CARBOXYLIC ACID DERIVATIVES THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2000-11-16 | — | — | WO | claimed |
| EP-1203766-B1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC (US) | 2012-02-29 | — | — | EP | disclosed |
| US-7812038-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| EP-1176956-B1 | CARBOXYLIC ACID DERIVATIVES THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS | ENCYSIVE PHARMACEUTICALS INC (US) | 2008-01-09 | — | — | EP | disclosed |
| US-20060276476-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | BIEDIGER RONALD J | 2006-12-07 | — | — | US | disclosed |
| US-6972296-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC. (US) | 2005-12-06 | — | — | US | disclosed |
| US-20040063955-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC. | 2004-04-01 | — | — | US | disclosed |
| WO-2000067746-A9 | CARBOXYLIC ACID DERIVATIVES THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS | TEXAS BIOTECHNOLOGY CORP (US) | 2002-08-29 | — | — | WO | disclosed |
| EP-1203766-A2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2002-05-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276476-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | VCAM1, ICAM1, ITGA1 | LCK 2396/4885PTGER3 2942/4885CTSA 686/4885 |
| US-20040063955-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | VCAM1, ICAM1, FN1 | LCK 2404/4885PTGER3 2649/4885CTSA 471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.